Abstract
Twenty-three patients with heptocellular carcinoma were treated with m-AMSA at a dose of 120 mg/m2 iv repeated at 4-week intervals. Toxicity was primarily hematologic. Partial responses occurred in two of 14 previously treated patients and in one of nine previously untreated patients. The overall activity of m-AMSA in patients with hepatocellular carcinoma appears minimal.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Aminoacridines / adverse effects
-
Aminoacridines / therapeutic use*
-
Amsacrine
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Hepatocellular / drug therapy*
-
Drug Evaluation
-
Female
-
Humans
-
Leukopenia / chemically induced
-
Liver Neoplasms / drug therapy*
-
Male
-
Middle Aged
Substances
-
Aminoacridines
-
Antineoplastic Agents
-
Amsacrine